These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 2526527

  • 1. Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils: a potential mast cell-eosinophil interaction.
    Parsons WG, Roberts LJ.
    Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():499-502. PubMed ID: 2526527
    [No Abstract] [Full Text] [Related]

  • 2. Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils. A potential mast cell-eosinophil interaction.
    Parsons WG, Roberts LJ.
    J Immunol; 1988 Oct 01; 141(7):2413-9. PubMed ID: 3139758
    [Abstract] [Full Text] [Related]

  • 3. Cross-talk between mast cells and eosinophils.
    Levi-Schaffer F.
    Allergy; 1999 Oct 01; 54 Suppl 58():36-8. PubMed ID: 10735648
    [No Abstract] [Full Text] [Related]

  • 4. Basophil and eosinophil interactions in health and disease.
    Thomas LL.
    Chem Immunol; 1995 Oct 01; 61():186-207. PubMed ID: 7662143
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Isomeric prostaglandin F2 compounds: a new family of eicosanoids produced in vivo in humans.
    Wendelborn DF, Seibert K, Roberts LJ.
    Adv Prostaglandin Thromboxane Leukot Res; 1987 Oct 01; 17A():47-9. PubMed ID: 2959099
    [No Abstract] [Full Text] [Related]

  • 10. Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting.
    Samoszuk M, Corwin M, Hazen SL.
    Am J Hematol; 2003 May 01; 73(1):18-25. PubMed ID: 12701115
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 5. IgE, mast cells, basophils, and eosinophils.
    Prussin C, Metcalfe DD.
    J Allergy Clin Immunol; 2006 Feb 01; 117(2 Suppl Mini-Primer):S450-6. PubMed ID: 16455345
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mast cells enhance eosinophil survival in vitro: role of TNF-alpha and granulocyte-macrophage colony-stimulating factor.
    Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y.
    J Immunol; 1998 Jun 01; 160(11):5554-62. PubMed ID: 9605160
    [Abstract] [Full Text] [Related]

  • 15. Extracellular release of rat eosinophil peroxidase (EPO) I. Role of anaphylactic immunoglobulins.
    Khalife J, Capron M, Grzych JM, Bazin H, Capron A.
    J Immunol; 1985 Mar 01; 134(3):1968-74. PubMed ID: 3968436
    [Abstract] [Full Text] [Related]

  • 16. Anti- and proinflammatory effects of 15-deoxy-delta-prostaglandin J2(15d-PGJ2) on human eosinophil functions.
    Ueki S, Kato H, Kobayashi Y, Ito W, Adachi T, Nagase H, Ohta K, Kayaba H, Chihara J.
    Int Arch Allergy Immunol; 2007 Mar 01; 143 Suppl 1():15-22. PubMed ID: 17541271
    [Abstract] [Full Text] [Related]

  • 17. Biosynthesis of prostaglandin F2 alpha from prostaglandins H2 and D2 by an apparently homogeneous enzyme.
    Watanabe K, Yoshida R, Shimizu T, Hayaishi O.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Mar 01; 15():151-3. PubMed ID: 2936081
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils.
    Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, Beri R, Sargent C, Schmidt JA, Lang-Loidolt D, Heinemann A.
    Eur J Clin Invest; 2008 Sep 01; 38(9):663-71. PubMed ID: 18837743
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.